Enanta Pharmaceuticals (ENTA) Short Interest Ratio & Short Volume $5.79 -0.28 (-4.61%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$5.80 +0.00 (+0.09%) As of 05/21/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Enanta Pharmaceuticals Short Interest DataEnanta Pharmaceuticals (ENTA) has a short interest of 2.96 million shares, representing 14.93% of the float (the number of shares available for trading by the public). This marks a 5.71% increase in short interest from the previous month. The short interest ratio (days to cover) is 9.1, indicating that it would take 9.1 days of the average trading volume of 285,483 shares to cover all short positions.Current Short Interest2,960,000 sharesPrevious Short Interest2,800,000 sharesChange Vs. Previous Month+5.71%Dollar Volume Sold Short$18.03 millionShort Interest Ratio9.1 Days to CoverLast Record DateApril 30, 2025Outstanding Shares21,377,000 sharesFloat Size19,820,000 sharesShort Percent of Float14.93%Today's Trading Volume156,188 sharesAverage Trading Volume285,483 sharesToday's Volume Vs. Average55% Short Selling Enanta Pharmaceuticals? Sign up to receive the latest short interest report for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartENTA Short Interest Over TimeENTA Days to Cover Over TimeENTA Percentage of Float Shorted Over Time Enanta Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20252,960,000 shares $18.03 million +5.7%14.9%9.1 $6.09 4/15/20252,800,000 shares $14.42 million +4.9%14.1%8.1 $5.15 3/31/20252,670,000 shares $14.74 million +1.5%13.5%6.3 $5.52 3/15/20252,630,000 shares $17.49 million +1.2%13.3%5.2 $6.65 2/28/20252,600,000 shares $20.23 million -27.2%13.1%4.6 $7.78 2/15/20253,570,000 shares $25.49 million +6.3%18.0%6.2 $7.14 1/31/20253,360,000 shares $17.17 million +4.0%16.9%6.9 $5.11 1/15/20253,230,000 shares $15.57 million -3.6%16.4%7.3 $4.82 12/31/20243,350,000 shares $19.26 million -0.6%17.0%8.8 $5.75 12/15/20243,370,000 shares $20.32 million +4.3%17.1%12.2 $6.03 Get the Latest News and Ratings for ENTA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/30/20243,230,000 shares $27.78 million -4.4%16.4%15.2 $8.60 11/15/20243,380,000 shares $32.21 million -1.7%17.2%20 $9.53 10/31/20243,440,000 shares $38.68 million +0.3%17.5%22 $11.25 10/15/20243,430,000 shares $40.03 million +14.7%17.4%20.7 $11.67 9/30/20242,990,000 shares $30.98 million +2.4%15.2%16.5 $10.36 9/15/20242,920,000 shares $36.30 million +0.3%14.8%16.9 $12.43 8/31/20242,910,000 shares $37.48 million -1.7%14.8%16.7 $12.88 8/15/20242,960,000 shares $36.29 million +5.7%15.0%16 $12.26 7/31/20242,800,000 shares $41.33 million -3.8%14.2%15.7 $14.76 7/15/20242,910,000 shares $48.13 million -3.3%14.8%16.6 $16.54 6/30/20243,010,000 shares $39.04 million +9.1%15.3%18.3 $12.97 6/15/20242,760,000 shares $35.44 million No Change14.0%15.3 $12.84 5/31/20242,760,000 shares $34.42 million -1.4%14.0%14.7 $12.47 5/15/20242,800,000 shares $37.35 million +0.7%14.2%14.5 $13.34 4/30/20242,780,000 shares $38.20 million +1.5%14.2%12.5 $13.74 4/15/20242,740,000 shares $44.25 million No Change13.9%12 $16.15 3/31/20242,740,000 shares $47.84 million +13.7%13.9%10.4 $17.46 3/15/20242,410,000 shares $34.25 million +15.3%12.3%9.2 $14.21 2/29/20242,090,000 shares $30.03 million -5.4%10.6%8 $14.37 2/15/20242,210,000 shares $29.30 million +20.1%11.2%8.2 $13.26 1/31/20241,840,000 shares $22.36 million +15.7%9.3%6.5 $12.15 1/15/20241,590,000 shares $17.82 million +2.6%8.1%5.4 $11.21 12/31/20231,550,000 shares $14.59 million -13.9%7.9%5.4 $9.41 12/15/20231,800,000 shares $16.81 million +22.5%9.2%6.4 $9.34 11/30/20231,470,000 shares $13.73 million -2.7%7.5%3.4 $9.34 11/15/20231,510,000 shares $13.21 million +12.7%7.7%3.3 $8.75 10/31/20231,340,000 shares $12.09 million +3.9%6.9%3.1 $9.02 10/15/20231,290,000 shares $12.42 million +8.4%6.6%3 $9.63 9/30/20231,190,000 shares $13.29 million -42.0%6.8%2.9 $11.17 9/15/20232,050,000 shares $26.10 million +22.0%10.5%5.2 $12.73Trump’s treachery (Ad)I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street seems to understand why. Like an addict who needs desperate help, Trump’s Treasury pick, Scott Bessent, is putting America through a “detox period” — and I think it’s going to be absolutely brutal for our economy. Why’s he doing this?You may have already noticed the effect on your portfolio as markets have begun to bleed. 8/31/20231,680,000 shares $24.95 million +16.7%8.6%6 $14.85 8/15/20231,440,000 shares $22.82 million No Change7.4%6.4 $15.85 7/31/20231,440,000 shares $27.32 million +5.9%7.4%6 $18.97 7/15/20231,360,000 shares $26.14 million +14.3%7.0%5.9 $19.22 6/30/20231,190,000 shares $25.47 million +47.3%6.2%5.3 $21.40 6/15/2023808,100 shares $19.54 million +2.3%4.2%3.7 $24.18 5/31/2023789,600 shares $18.54 million +18.2%4.1%3.9 $23.48 5/15/2023667,800 shares $17.28 million -6.4%3.5%3.4 $25.87 4/30/2023713,500 shares $25.36 million -2.4%3.7%3.8 $35.55 4/15/2023730,800 shares $26.70 million +4.8%3.8%4.2 $36.53 3/31/2023697,100 shares $28.19 million -22.6%3.6%3.9 $40.44 3/15/2023900,100 shares $40.06 million +20.0%4.7%5.3 $44.51 2/28/2023750,300 shares $36.39 million -8.4%3.9%4.8 $48.50 2/15/2023819,500 shares $41.12 million -3.8%4.3%5.1 $50.18 1/31/2023851,400 shares $45.45 million +0.4%4.4%5.5 $53.38 1/15/2023847,700 shares $43.62 million -1.6%4.4%5 $51.46 12/30/2022861,500 shares $40.08 million -6.0%4.5%5 $46.52 12/15/2022916,400 shares $40.17 million -11.9%4.8%5.1 $43.84 11/30/20221,040,000 shares $45.54 million +4.2%5.4%5.4 $43.79 11/15/2022998,400 shares $47.14 million -4.0%5.2%4.9 $47.22 10/31/20221,040,000 shares $46.91 million -17.5%5.4%5.1 $45.11 10/15/20221,260,000 shares $59.16 million -2.3%6.5%6 $46.95 9/30/20221,290,000 shares $66.91 million -5.2%6.7%6.4 $51.87 9/15/20221,360,000 shares $78.77 million -8.1%7.0%6.1 $57.92 8/31/20221,480,000 shares $90.10 million -3.3%7.7%6.1 $60.88 8/15/20221,530,000 shares $107.80 million -8.9%7.9%6.1 $70.46 7/31/20221,680,000 shares $92.65 million +3.1%8.7%5.8 $55.15 7/15/20221,630,000 shares $83.64 million -1.8%8.4%5.9 $51.31 6/30/20221,660,000 shares $78.47 million +5.7%8.6%5.8 $47.27 6/15/20221,570,000 shares $62.80 million +6.1%10.7%5.8 $40.00 5/31/20221,480,000 shares $59.10 million +10.5%7.7%6.2 $39.93 5/15/20221,340,000 shares $66.84 million +10.7%6.9%5.5 $49.88 4/30/20221,210,000 shares $77.92 million +9.0%6.3%5.6 $64.40 4/15/20221,110,000 shares $82.42 million -5.9%5.8%5.2 $74.25 3/31/20221,180,000 shares $83.99 million +9.3%6.1%5.4 $71.18 3/15/20221,080,000 shares $70.87 million +21.9%5.6%5.1 $65.62 2/28/2022886,300 shares $62.41 million +13.7%4.6%4 $70.42 2/15/2022779,800 shares $48.51 million -16.5%4.1%3.5 $62.21 1/31/2022933,700 shares $55.48 million +28.6%5.2%4.3 $59.42 1/15/2022726,100 shares $43.57 million +4.0%N/A0 $60.00 12/31/2021697,900 shares $52.19 million -2.4%3.9%3.5 $74.78 12/15/2021715,300 shares $52.22 million +5.4%4.0%3.6 $73.00 11/30/2021678,900 shares $59.93 million -0.3%3.8%3.7 $88.28 11/15/2021681,000 shares $61.21 million -36.9%3.8%4 $89.88 10/29/20211,080,000 shares $92.72 million -32.1%6.1%6.7 $85.85 10/15/20211,590,000 shares $113.64 million -9.7%8.9%10.8 $71.47 9/30/20211,760,000 shares $99.99 million -2.8%9.9%11.8 $56.81 9/15/20211,810,000 shares $106.16 million -7.2%10.1%11.7 $58.65 8/31/20211,950,000 shares $111.54 million -8.9%10.9%12 $57.20 8/13/20212,140,000 shares $100.90 million +4.9%12.0%13.8 $47.15Trump’s treachery (Ad)I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street seems to understand why. Like an addict who needs desperate help, Trump’s Treasury pick, Scott Bessent, is putting America through a “detox period” — and I think it’s going to be absolutely brutal for our economy. Why’s he doing this?You may have already noticed the effect on your portfolio as markets have begun to bleed. 7/30/20212,040,000 shares $86.19 million +9.1%11.4%13.8 $42.25 7/15/20211,870,000 shares $78.73 million +7.5%10.5%13.5 $42.10 6/30/20211,740,000 shares $76.58 million -7.0%9.8%13.4 $44.01 6/15/20211,870,000 shares $89.57 million -1.6%10.5%15.6 $47.90 5/28/20211,900,000 shares $92.45 million -4.0%10.6%16.9 $48.66 5/14/20211,980,000 shares $99.59 million -2.5%11.1%15.3 $50.30 4/30/20212,030,000 shares $104.24 million -5.1%11.4%14.8 $51.35 4/15/20212,140,000 shares $108.39 million -2.7%12.0%14.6 $50.65 3/31/20212,200,000 shares $105.75 million +1.4%12.3%14.4 $48.07 3/15/20212,170,000 shares $113.25 million +0.5%12.2%13.2 $52.19 2/26/20212,160,000 shares $109.25 million +1.4%12.1%13.1 $50.58 2/12/20212,130,000 shares $114.66 million -9.0%12.0%13.4 $53.83 1/29/20212,340,000 shares $107.83 million -1.7%13.2%14.8 $46.08 1/15/20212,380,000 shares $115.05 million -1.2%13.4%14.3 $48.34 12/31/20202,410,000 shares $100.11 million +5.2%13.6%14.3 $41.54 12/15/20202,290,000 shares $97.33 million -3.0%12.9%13.5 $42.50 11/30/20202,360,000 shares $101.24 million -2.9%13.4%13.7 $42.90 11/15/20202,430,000 shares $109.64 million -2.0%13.7%13.9 $45.12 10/30/20202,480,000 shares $108.92 million +15.4%14.0%14.2 $43.92 10/15/20202,150,000 shares $95.78 million +3.4%12.1%12.5 $44.55 9/30/20202,080,000 shares $95.22 million -2.8%11.7%12.7 $45.78 9/15/20202,140,000 shares $100.07 million +5.4%12.1%12.6 $46.76 8/31/20202,030,000 shares $105.95 million +4.1%11.5%12.5 $52.19 8/14/20201,950,000 shares $95.08 million -0.5%11.0%12.2 $48.76 7/31/20201,960,000 shares $89.87 million +3.2%11.1%12.2 $45.85 7/15/20201,900,000 shares $98.17 million +2.2%10.8%12.2 $51.67 6/30/20201,860,000 shares $91.21 million +10.7%10.5%11.7 $49.04 6/15/20201,680,000 shares $81.51 million +5.0%9.5%10.4 $48.52 5/29/20201,600,000 shares $82.56 million +0.6%9.1%8.2 $51.60 ENTA Short Interest - Frequently Asked Questions What is Enanta Pharmaceuticals' current short interest? Short interest is the volume of Enanta Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 2,960,000 shares of ENTA short. 14.93% of Enanta Pharmaceuticals' shares are currently sold short. Learn More on Enanta Pharmaceuticals' current short interest. What is a good short interest ratio for Enanta Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ENTA shares currently have a short interest ratio of 9.0. Learn More on Enanta Pharmaceuticals's short interest ratio. Which institutional investors are shorting Enanta Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Enanta Pharmaceuticals: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Enanta Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 14.93% of Enanta Pharmaceuticals' floating shares are currently sold short. Is Enanta Pharmaceuticals' short interest increasing or decreasing? Enanta Pharmaceuticals saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 2,960,000 shares, an increase of 5.7% from the previous total of 2,800,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Enanta Pharmaceuticals' float size? Enanta Pharmaceuticals currently has issued a total of 21,377,000 shares. Some of Enanta Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Enanta Pharmaceuticals currently has a public float of 19,820,000 shares. How does Enanta Pharmaceuticals' short interest compare to its competitors? 14.93% of Enanta Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Enanta Pharmaceuticals: Relay Therapeutics, Inc. (11.36%), REGENXBIO Inc. (10.31%), Zevra Therapeutics, Inc. (10.35%), Amylyx Pharmaceuticals, Inc. (6.30%), Arvinas, Inc. (10.14%), Ginkgo Bioworks Holdings, Inc. (31.09%), Cullinan Therapeutics, Inc. (20.91%), Altimmune, Inc. (27.84%), Sage Therapeutics, Inc. (8.48%), Tectonic Therapeutic (11.36%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short Enanta Pharmaceuticals stock? Short selling ENTA is an investing strategy that aims to generate trading profit from Enanta Pharmaceuticals as its price is falling. ENTA shares are trading down $0.28 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Enanta Pharmaceuticals? A short squeeze for Enanta Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ENTA, which in turn drives the price of the stock up even further. How often is Enanta Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENTA, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies Relay Therapeutics Short Interest Data REGENXBIO Short Interest Data Zevra Therapeutics Short Interest Data Amylyx Pharmaceuticals Short Interest Data Arvinas Short Interest Data Ginkgo Bioworks Short Interest Data Cullinan Therapeutics Short Interest Data Altimmune Short Interest Data Sage Therapeutics Short Interest Data Tectonic Therapeutic Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ENTA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENTA Stock Free ENTA Stock Alerts